- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04079842
Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00029
22 september 2022 uppdaterad av: Masimo Corporation
ORi is a unitless index that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00.
An ORi of 0.00 corresponds to PaO2 values of 100mmHg and below, and an ORi of 1.00 corresponds to PaO2 values of 200mmHg and above.
In this study, the PaO2 is varied by controlling the concentration of oxygen the study volunteer breathes.
Changes in ORi values are analyzed by comparing it to corresponding changes in PaO2 measurements from blood samples.
Studieöversikt
Studietyp
Interventionell
Inskrivning (Faktisk)
29
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
Irvine, California, Förenta staterna, 92618
- Masimo Corporation
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 50 år (Vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall.
- Hemoglobin value is greater than or equal to 11 g/dL.
- Baseline heart rate ≥ 45 bpm and ≤ 85 bpm.
- Carbon monoxide (CO) value ≤ 2.0% fractional carboxyhemoglobin (FCOHb).
- Subject has a physical status of ASA I or II (American Society of Anesthesiology Class 1; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) as it applies to the systemic disease portion of the classification.
- Blood Pressure: (Systolic Blood Pressure ≤ 140 mmHg and ≥ 90 mmHg, Diastolic Blood Pressure ≤ 90 mmHg and ≥ 50 mmHg), and if blood pressure is lower than 100/60 subject passes an orthostatic blood pressure test
- Subject is able to read and communicate in English and understands the study and risks involved.
Exclusion Criteria:
- Subject is pregnant.
- Subject has a BMI > 35 and has been classified as morbidly obese or at an increased risk for participation by a medical professional.
- Subject has a history of fainting (vasovagal), blacking out or losing consciousness during or after a blood draw, or has a fear of blood draws.
- Subject smokes one pack of cigarettes or more in one week, and/or the equivalent of e-cigarette liquid, and smokers are not being recruited as indicated in the CSRF.
- Subject has open wounds, inflamed tattoos or piercings and/or any visible healing wounds that a medical professional renders them at an increased risk for participation (per physician discretion).
- Subject has known drug or alcohol abuse or uses recreational drugs.
- Subject experiences frequent or severe headaches and/or migraine headaches, migraine auras, altitude sickness, and/or headaches accompanied by visual changes or sensitivity to light or sound.
- Subject has experienced a concussion or head injury with loss of consciousness within the past 12 months.
- Subject has any history of a stroke, myocardial infarction, seizures or heart attack.
- Subject who has taken anticoagulant medications within the last 30 days (excluding nonsteroidal anti-inflammatory drugs (NSAIDS).
- Subject has donated blood within the past 4 weeks.
- Subject has any chronic bleeding disorder (i.e. hemophilia)
- Subject has any symptomatic cardiac dysrhythmia (i.e. atrial fibrillation) and has not received clearance from their physician to participate.
- Subject has Wolff-Parkinson-White Syndrome or Stokes - Adams syndrome.
- Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder, Multiple Sclerosis, Huntington's disease) that interferes with the subjects' level of consciousness.
- Subject has taken opioid pain medication within 24 hours of start of study.
- Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu, Malaria, Measles, etc.).
- Subject is taking medications known to treat any type of infectious disease (per physician discretion).
- Subject has either signs or history of peripheral ischemia or carpal tunnel syndrome.
- Subject has had invasive surgery within the past year- including but not limited to major dental surgery, appendix, plastic surgery (per physician discretion).
- Subject has had invasive surgery within the past year- including but not limited to gallbladder, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery.
- Subject has symptoms of congestion, head cold, flu or other illnesses.
- Subject is claustrophobic and/or has generalized anxiety disorder.
- Subject has been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the past 12 months.
- Subject has any cancer or history of cancer (not including skin cancer), per physician discretion.
- Subject has chronic unresolved asthma, lung disease (including COPD) and/or respiratory disease.
- Subject is allergic to lidocaine, latex, adhesives, or plastic.
- Subject has a heart condition, insulin-dependent Diabetes, or uncontrolled hypertension.
- Subject has delivered vaginally, has had a pregnancy terminated, a miscarriage with hospitalization, or had a C-section within the past 6 months.
- Subject intends to participate in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle, tennis) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study that involved an arterial line.
- Subject has any medical condition which in the judgement of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator/study staff).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: INVSENSOR00029
All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
|
Noninvasive pulse oximeter sensor
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Känslighet för förändringar i ORi-värden jämfört med motsvarande förändringar i PaO2-värden.
Tidsram: 1 till 5 timmar per ämne
|
ORi är ett indexvärde utan enhet och ORi mäter inte direkt PaO2.
Därför beräknas sensitivitet, specificitet och konkordans för att utvärdera förändringar i ORi i förhållande till förändringarna i PaO2.
|
1 till 5 timmar per ämne
|
|
Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values
Tidsram: 1-5 hours per subject
|
ORi is an index value without a unit and ORi does not directly measure PaO2.
Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.
|
1-5 hours per subject
|
|
Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values.
Tidsram: 1 to 5 hours per subject
|
ORi is an index value without a unit and ORi does not directly measure PaO2.
Therefore, sensitivity, specificity, and concordance are calculated to evaluate changes in ORi relative to the changes in PaO2.
|
1 to 5 hours per subject
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
20 augusti 2019
Primärt slutförande (Faktisk)
28 augusti 2019
Avslutad studie (Faktisk)
28 augusti 2019
Studieregistreringsdatum
Först inskickad
3 september 2019
Först inskickad som uppfyllde QC-kriterierna
3 september 2019
Första postat (Faktisk)
6 september 2019
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
19 oktober 2022
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 september 2022
Senast verifierad
1 september 2022
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- TP-20088
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .